QTI — QT Imaging Holdings, Inc.
Is QTI overbought or oversold? Here is the current MarketMoodz read.
QT Imaging Holdings, Inc. (QTI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $1.80. The rating moved from Oversold to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$1.80
- Last changeMoved from Oversold to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
QT Imaging Holdings, Inc. (QTI) is a small-cap medical/device company with limited public disclosure and modest visibility into financial health. Sector trends toward outpatient care and distributor shifts offer constructive readthroughs, and discrete catalysts (regulatory clearance, reimbursement wins, partnerships or distributor agreements) could drive episodic upside. However, execution risk, potential dilution to raise capital, regulatory/reimbursement uncertainty, and low liquidity make near-term performance highly binary. Expect price action to be driven by newsflow; absent clear positive developments, performance is likely to remain muted with elevated volatility.
Key factors
- Niche medical-imaging/device exposure with potential readthrough from sector shifts toward outpatient and at‑home care
- Limited publicly available recent filings and social/research coverage, reducing visibility into near-term financial health
- Potential catalysts include regulatory decisions, commercialization/partnership announcements, and reimbursement progress
- Market tone is modestly constructive for growth/healthcare names, which could support episodic upside on positive news
- Small-cap / microcap characteristics (low liquidity, high volatility) that amplify both upside on catalysts and downside on adverse developments
Risks
- Limited disclosure or recent EDGAR filings increases uncertainty around cash runway and operating performance
- Dilution risk from potential equity or convertible financings if cash is limited (sector convertible-debt pressure noted)
- Regulatory and reimbursement hurdles that could delay or limit commercial adoption
- Concentration risk (dependence on a single product, narrow customer base, or a small set of distributor/partner relationships)
- Competitive pressure from larger device and imaging players and faster-to-market alternatives
- Low liquidity and high share-price volatility, making the stock sensitive to trading flows and headlines
See today's live rating, score and targets
Members see the live hourly rating for QTI — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.